InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS). Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial.
Additionally, William Gray, M.D., system chief of the cardiovascular division at Main Line Health in Wynnewood, PA and professor of medicine at Thomas Jefferson University in Philadelphia, PA, will act as an advisor to the Company.
Marvin Slosman, chief executive officer of InspireMD, stated, “As the only company with a mission to develop solutions that support both CAS and TCAR carotid revascularization procedures with a best-in-class implant, we consider initiation of the C-GUARDIANS II clinical trial of our SwitchGuard™ Neuroprotection System as a very significant upcoming milestone for our company. We are very pleased that Drs. Geraghty and Muck, both recognized leaders in the field of vascular surgery, have agreed to lead the execution of this important trial, planned to start later this year. We also welcome William Gray, M.D., as an advisor to the Company and look forward to his contributions given his vast experience and knowledge in the field of carotid intervention.”
“We are very fortunate and grateful to have built an incredible a team of supporters and advocates for C-GUARDIANS II, as we did with the previously enrolled C-GUARDIANS trial, advancing our goal of establishing CGuard Prime as the leading carotid implant.”
The C-GUARDIANS II study is intended to advance clearance of SwitchGuard™ NPS and associated tools, designed to allow the treating physician to reverse cerebral blood flow during a TCAR procedure, thus preventing embolic debris generated during the procedure from traveling to the brain, passing the blood through the filter housed within the SwitchGuard™ before returning it to the patient to minimize blood loss.
About InspireMD, Inc.
We routinely post iformation that may be important to investors on our website. For more information, please visit www.inspiremd.com.